^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Versamune HPV

    i
    Company:
    PDS Biotech
    Drug class:
    Immunostimulant, HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
    Related drugs:
    Apply
    Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies (NCT04287868)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    06/09/2020
    Primary completion :
    07/26/2022
    Completion :
    07/01/2026
    PD-L1 • CDKN2A • CD4
    |
    PD-L1 negative
    |
    bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC
    Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC (VERSATILE-002) (NCT04260126)
    Phase 2
    PDS Biotechnology Corp.
    Active, not recruiting
    Last update posted :
    12/18/2024
    Initiation :
    03/29/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Versamune HPV
    A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial (NCT04580771)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    10/14/2020
    Primary completion :
    03/08/2025
    Completion :
    03/08/2025
    ALK
    |
    cisplatin • Versamune HPV